Insider sales
Jonathan Allan, who serves as General Counsel and Corporate Secretary at Stoke Therapeutics, Inc. (NASDAQ: STOK), reported sales of 8,995 shares of common stock executed on March 17 and March 18, 2026, for aggregate proceeds of roughly $285,900. The transactions were disclosed as mandated sales to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units.
Transaction breakdown
- On March 17, Allan sold 2,476 shares at a weighted average price of $32.7394 per share, with individual trade prices spanning $31.995 to $32.99.
- Also on March 17, he sold an additional 1,791 shares at a weighted average price of $33.3754 per share; individual prices for those trades ranged from $33.00 to $33.855.
- On March 18, Allan sold 4,222 shares at a weighted average price of $31.2838 per share, with prices in that block ranging from $30.59 to $31.58.
- That same day he sold 334 shares at an average price of $31.7888 per share, with individual prices between $31.60 and $32.46.
- The final reported transaction was for 72 shares, sold at $32.85 each.
Following these mandated sales, Allan is reported to directly own 28,836 shares of Stoke Therapeutics.
Corporate developments and market context
In separate corporate news, Stoke Therapeutics' Board of Directors approved a discretionary cash bonus of $697,125 for CEO Ian F. Smith. The company said the bonus reflects the firm's clinical and financial performance since Mr. Smith assumed the CEO role.
On the analyst and regulatory fronts, Guggenheim has initiated coverage on Stoke with a Buy rating and set a price target of $60.00, citing the potential of Stoke's lead asset, zorevunersen, which the analyst characterizes as a disease-modifying candidate for Dravet syndrome. Cantor Fitzgerald has maintained an Overweight rating on the company while discussions with the U.S. Food and Drug Administration continue about potential expedited regulatory pathways. The FDA has requested additional information on the BUTTERFLY trial data, and Stoke has indicated readiness to provide the requested material.
Stoke has also disclosed a delay to the timeline for its Phase 3 EMPEROR study, a development that precipitated a notable decline in the company’s share price. The company now expects to complete patient enrollment in the second quarter of 2026, with a data readout targeted for mid-2027.
What is clear
The reported insider sales were disclosed as procedural, tax-related transactions tied to RSU vesting and settlement. At the same time, the company is navigating both analyst coverage and ongoing regulatory review while adjusting clinical timelines for a Phase 3 program. Those factors are currently influencing investor attention and market pricing for the stock.